drugset / Trial / NCT01352611

Open Label Treatment of Severe Tactile Defensiveness With Intrathecal Baclofen

NCT01352611

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if intrathecal administration of baclofen can reduce symptoms of severe tactile defensiveness and autism spectrum disorder.

Timeline

Start
2014-09
Primary completion
2015-04
Completion
2015-04

Publications

  • Background Farid, R.S., Nevel, R. and Murdock, F. Effect of Intrathecal Baclofen on Severe Tactile Defensiveness and Symptoms of Autism Spectrum Disorder. Abstract. International Meeting for Autism Research, Philadelphia, PA. May, 2010.

Drugs

EvaluationDrugModalityDoseRoute
Subject Baclofen Small molecule 50 ug Intrathecal